I think a safety comparison chart against competitors would be great. I don't see anything like this clearly listed on CYDY website, which I think is extremely important and one that makes leronlimab far superior to others....here is a pretty good one I copied from the EG article from a couple of months ago.



I also think a chart showing efficacy results across indications would be nice. Hopefully you receive CYDY's support and help get the word out to new patients and investors!

https://emerginggrowth.com/bio-path-nasdaq-bp...-analysis/